fbpx Skip to main content

Member's Profile

Releviate Therapeutics, LLC

10210 Campus Point Drive Suite 150
San Diego,   California
United States
Membership Info
Membership Type: Industry
Membership Since: 2021
Need to make an update to your Member Profile or have a question? Contact us here: [email protected]
About Releviate Therapeutics, LLC
Biotech Company
Our therapeutic strategy deploys specific human monoclonal antibodies to inactivate certain matrix metalloproteinases – MMP-9 and MMP-14. Our therapy can potentially improve outcomes for patients suffering from severe neuropathic pain, whose only current treatment option is opioids, which can be addictive and cause sever side effects. Patients suffering from moderate chronic pain who are currently dependent on anti-seizure and anti-depressant medications, can also potentially benefit from Releviate therapy. Our studies will further test the safety and efficacy of our therapeutic.
Related News
Releviate Therapeutics Inks Exclusive License for Human Monoclonal Antibodies for Chronic Pain Indications
October 28, 2020
... Read more.